Alzheon to Make Presentations at Upcoming Industry and Medical Conferences
Company to Present Clinical Data at the 11th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference in October 2018
FRAMINGHAM, Mass., September 12, 2018 – Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that the company will be making presentations at upcoming drug development and medical conferences in this upcoming Fall, highlighting the company’s scientific discoveries and drug development for Alzheimer’s and neurodegenerative diseases.
Alzheon will be presenting the latest clinical data supporting the advancement of ALZ‑801 to a pivotal program as an oral precision medicine to treat Alzheimer’s disease at the 11th Annual Clinical Trials on Alzheimer’s Disease (CTAD) congress to be held on October 24-27, 2018 in Barcelona, Spain. Two poster presentations at CTAD highlight Alzheon’s lead drug candidate, ALZ-801, an orally-administered, anti-amyloid inhibitor that blocks the formation of toxic amyloid oligomers associated with the development and progression of AD. The results presented at CTAD further support the pivotal Phase 3 development of ALZ-801 as a Precision Medicine approach to treat Alzheimer’s patients with apolipoprotein E4 (APOE4) genotype, with future expansion to additional Alzheimer’s populations.
In addition to the clinical data presentations at CTAD, Alzheon will also be making presentations at several industry conferences this Fall, highlighting the company’s scientific discoveries and pioneering Precision Medicine approach to Alzheimer’s disease. The details of the upcoming Fall presentations are as follows:
Event: The National Alzheimer’s Summit sponsored by UsAgainstAlzheimer’s
- Panel Presentation: The Alzheimer’s Drug Development Pipeline: Sustaining Hope on the Path to 2025
- Speaker: Martin Tolar, MD, PhD, Founder, President & CEO, Alzheon, Inc.
- Date: Tuesday, September 25 at 9:00 a.m.
- Location: Washington, D.C.
Event: Neuro Advance
- Panel Presentation: New Paradigms in Treating Neurodegenerative Disorders
- Speaker: Martin Tolar, MD, PhD, Founder, President & CEO, Alzheon, Inc.
- Date: Wednesday, October 10 at 12:15 p.m.
- Location: Harvard Medical School, Boston, Mass.
Event: 11th Clinical Trials on Alzheimer’s Disease (CTAD)
- Presentations: Two poster presentations with clinical data and results supporting advancement of ALZ-801 into late stage confirmatory trials as an oral precision medicine for AD
- Speakers: Susan Abushakra, MD, Chief Medical Officer and John Hey, PhD, Chief Scientific Officer, Alzheon, Inc.
- Date: October 24-27, 2018
- Location: Barcelona, Spain
“We look forward to these medical and industry forums where we can share our scientific discoveries and pioneering Precision Medicine approach to Alzheimer’s disease with colleagues around the world,” said Martin Tolar, MD, PhD, Founder, President and CEO of Alzheon. “Our recent findings bring new insights to the field and open the path to develop ALZ-801 as the first drug in a new class of medicines that intervenes in the formation of neurotoxic amyloid oligomers, and offers disease-modifying potential in Alzheimer’s as well as other currently untreatable neurological disorders.”
About ALZ-801
ALZ-801, a novel, oral anti-amyloid drug candidate is an optimized prodrug of tramiprosate that has shown promising results in analyses of Phase 3 clinical data.1,2 ALZ-801 received Fast Track designation from the U.S. Food and Drug Administration (FDA) in October 2017. The clinical data for ALZ-8014 and its active agent, tramiprosate, indicate long-term clinical efficacy in AD patients with the APOE4 genotype, along with a favorable safety profile.1,2 ALZ-801 acts through a novel molecular mechanism of action blocking the formation of toxic amyloid oligomers3,5 considered key drivers of the pathogenesis and progression of AD. The initial Phase 3 program for ALZ-801 will focus on patients with the homozygous APOE4/4 genotype at the mild to moderate stage of AD, with the potential for future expansion to additional Alzheimer’s populations.
About Alzheon
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of beta amyloid aggregation and neurotoxicity – hallmarks of Alzheimer’s disease. ALZ-801 is a novel prodrug that builds on the safety and efficacy profile of the active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform are focused on developing drug candidates using a Precision Medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients.
1 Abushakra et al. Journal of Prevention of Alzheimer’s Disease, 2016
2 Abushakra et al. Journal of Prevention of Alzheimer’s Disease, 2017
3 Kocis et al. CNS Drugs, 2017
4 Hey et al. Clinical Pharmacokinetics, 2018
5 Hey et al. CNS Drugs, 2018
Contact:
Kathryn Morris
The Yates Network
914-204-6412